Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Deal Watch

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

UCB looks to pipeline with five years left for twin blockbusters

CEO outlines pipeline promise, won't write off post-Brexit UK

- PMLiVE

Pharma industry swamped with no-deal Brexit info, says BIA

Deluge comes just as prime minister hints at delay

- PMLiVE

Intercept NASH drug closes in on FDA approval

Although the drug failed to meet secondary endpoint

- PMLiVE

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

UK market would be relegated in importance

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

No deal Brexit would see UK miss out on ‘safest medicines system in the world’

Health leaders say it would be 'a travesty'

- PMLiVE

Galapagos expands presence in fibrosis, NASH with Evotec deal

As lead candidate filgotinib nears filing, firm looks to expand horizons

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

Skills shortage and Brexit will hit R&D, warns UK pharma

Skill shortages and Brexit seen as greatest threat

- PMLiVE

Medicines will take priority over food in no-deal Brexit

The UK is more reliant on the EU for medicines than food, says Hancock

- PMLiVE

European Medicines Agency departs London ahead of Brexit

Regulator moving to Amsterdam, as Novartis adds voice to no-deal warnings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links